A solid platform with unique business model
- Leading market positions – 7th largest in the US1 and 2nd largest in MENA2
- Expanding manufacturing footprint - 29 plants across our markets, with additional facilities being established
- Global player with local expertise
- Trusted partner known for our commitment to quality and reliability of supply
- Agile supply chain, flexible manufacturing and leading technical capabilities
Highlights
An increasingly diverse portfolio and pipeline
- A broad portfolio that is tailored to local market needs
- Targeting increase in R&D spend to 6–7% of Group revenue to ensure the consistent development of new products
- Growing presence in specialty, complex and higher-value products, which offer less competition and higher margins
- Strong momentum in new product launches across our markets
- Enhancing our pipeline by adding innovative products through value-creating partnerships
- Adding to the strength of our base business through strategic acquisitions
Highlights
Strategic execution driven by our three pillars
A proven track record of delivery for shareholders
- Group revenue compound annual growth rate (CAGR) of 7% and core EBIT CAGR of 7% since 2019
- Strong cash generation with $564 million operating cash flow in 2024
- Strong balance sheet that provides financial flexibility to support future growth, with low leverage of 1.4x net debt to EBITDA
- High returns, with 16.9% return on average invested capital
Highlights
All figures for year ending 31 December 2024.
Latest news
Related content
Recent results
1. IQVIA MAT December 2024, includes all generic injectable and non-injectables
2. Based on internal analysis by using data from the following source: IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: calendar year 2024, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.